Publications by authors named "Scot Styren"

Claim this Profile
D
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.
Jennifer L W Da, Vanessa L Merker, Justin T Jordan, K Ina Ly, Alona Muzikansky, Scot Styren

Contemp Clin Trials· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.
Jaren W Landen, Sharon Cohen, Clare B Billing, Carol Cronenberger, Scot Styren

Alzheimers Dement (N Y)· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan, Scot Styren

Alzheimers Res Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
Alberto Russu, Mahesh N Samtani, Steven Xu, Omoniyi J Adedokun, Ming Lu, Scot Styren

J Alzheimers Dis· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.
Mahesh N Samtani, Steven X Xu, Alberto Russu, Omoniyi J Adedokun, Ming Lu, Scot Styren

Alzheimers Dement (N Y)· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.
Steven X Xu, Mahesh N Samtani, Alberto Russu, Omoniyi J Adedokun, Ming Lu, Scot Styren

Alzheimers Dement (N Y)· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.
Aaron H Burstein, Qinying Zhao, Joel Ross, Scot Styren, Jaren W Landen

Clin Neuropharmacol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease.
Elliott J Mufson, Milos D Ikonomovic, Scot D Styren, Scott E Counts, Joanne Wuu

Arch Neurol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.
Steven T DeKosky, Milos D Ikonomovic, Scot D Styren, Laurel Beckett, Stephen Wisniewski

Ann Neurol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis